{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:48:59Z","timestamp":1793911739781,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFC0840606"],"award-info":[{"award-number":["2019YFC0840606"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2016B030230003"],"award-info":[{"award-number":["2016B030230003"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81530046"],"award-info":[{"award-number":["81530046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81621001"],"award-info":[{"award-number":["81621001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770189"],"award-info":[{"award-number":["81770189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070189"],"award-info":[{"award-number":["82070189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015809","name":"Health Medical Collaborative Innovation Program of Guangzhou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["201704020214"],"award-info":[{"award-number":["201704020214"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.scib.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:25:59Z","timestamp":1623072359000},"page":"2498-2505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial"],"prefix":"10.1016","volume":"66","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Fa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2021.06.002_b0005","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2021.06.002_b0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2021.06.002_b0015","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.scib.2021.06.002_b0020","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from GruppoItaliano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942\u20137.","DOI":"10.1182\/blood.V98.10.2942"},{"key":"10.1016\/j.scib.2021.06.002_b0025","doi-asserted-by":"crossref","unstructured":"Xu LP, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 2018;11:33.","DOI":"10.1186\/s13045-018-0564-x"},{"key":"10.1016\/j.scib.2021.06.002_b0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0035","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.scib.2021.06.002_b0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.scib.2021.06.002_b0045","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/S2352-3026(18)30214-X","volume":"6","author":"Bonifazi","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.scib.2021.06.002_b0050","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.scib.2021.06.002_b0055","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912\u20139.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"10.1016\/j.scib.2021.06.002_b0060","doi-asserted-by":"crossref","unstructured":"Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123:3664-71.","DOI":"10.1182\/blood-2014-01-552984"},{"key":"10.1016\/j.scib.2021.06.002_b0065","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbmt.2005.09.012","volume":"12","author":"Rizzo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbmt.2013.01.026","article-title":"Nonmalignant late effects in survivors of partially matched donor hematopoietic stem cell transplantation","volume":"19","author":"Mo","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0085","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.scib.2018.08.008","article-title":"The role of collateral related donors in haploidentical hematopoietic stem cell transplantation","volume":"63","author":"Mo","year":"2018","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2021.06.002_b0090","doi-asserted-by":"crossref","unstructured":"Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015;125:1333\u20138.","DOI":"10.1182\/blood-2014-10-609032"},{"key":"10.1016\/j.scib.2021.06.002_b0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.scib.2021.06.002_b0100","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.scib.2021.06.002_b0105","doi-asserted-by":"crossref","first-page":"620891","DOI":"10.3389\/fimmu.2020.620891","article-title":"Co-reactivation of cytomegalovirus and Epstein-Barr virus was associated with poor prognosis after allogeneic stem cell transplantation","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2021.06.002_b0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","article-title":"The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.scib.2021.06.002_b0115","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(17)30417-5","article-title":"Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Locatelli","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2021.06.002_b0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/bmt.2012.99","article-title":"Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse","volume":"48","author":"Hoegh-Petersen","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0125","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbmt.2019.06.008","article-title":"Early cytomegalovirus reactivation and expansion of CD56bright CD16dim\/- DNAM1+ natural killer cells are associated with antileukemia effect after haploidentical stem cell transplantation in acute leukemia","volume":"25","author":"Jang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0130","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41409-020-0831-7","article-title":"Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes","volume":"55","author":"Ru","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.scib.2021.06.002_b0135","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3760\/cma.j.issn.0366-6999.20122752","article-title":"Risk factors for bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cell transplantation","volume":"126","author":"Mo","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.scib.2021.06.002_b0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.2011.38.4594","article-title":"Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation","volume":"30","author":"Khera","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.scib.2021.06.002_b0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2021.06.002_b0150","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","article-title":"Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial","volume":"4","author":"Finke","year":"2017","journal-title":"Lancet Haematol"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927321004072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927321004072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:48:04Z","timestamp":1761868084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927321004072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2095927321004072"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2021.06.002","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.","name":"copyright","label":"Copyright"}]}}